Login to Your Account

Deals And M&A NEWS

SHANGHAI – Zai Labs Ltd., of Shanghai, signed a China rights deal, including Hong Kong and Macau, for a coveted late-stage targeted non-small-cell lung cancer (NSCLC) therapy, HM61713, from Hanmi Pharmaceuticals Co. Ltd., of Seoul, South Korea.

HONG KONG – 3Sbio Inc., a biopharmaceutical company that has returned to a stock market in China after delisting abroad, has taken a further step in its newfound home market by acquiring shares of a leading biosimilar MAb maker to build the largest biological drug platform in China.

DUBLIN – Pierre Fabre SA is paying Array Biopharma Inc. $30 million up front plus up to $425 million more in milestones for European, Asian and Latin American rights to binimetinib and encorafenib.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: